"/><span class=\\\"Bold\\\">Do not</span> put the Needle Cap back on; this could damage the needle.<br/><br/><span class=\\\"Bold\\\">Do not</span> touch the Needle.</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">2</span></td><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Pinch the injection site and insert the Needle</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" valign=\\\"top\\\"><a name=\\\"f11\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"ebglyss-pfs-ifu-7-v1.jpg\\\"/></td><td align=\\\"justify\\\" valign=\\\"middle\\\">Gently pinch a fold of skin at the injection site with one hand.<br/>Insert the Needle completely into the fold of skin at about a 45º angle with your other hand.</td></tr><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" rowspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">3</span></td><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Push in the Plunger Rod</span></td><td align=\\\"left\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"center\\\" valign=\\\"top\\\"><a name=\\\"f12\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"ebglyss-pfs-ifu-8-v1.jpg\\\"/></td><td align=\\\"left\\\" valign=\\\"top\\\">Gently relax the pinch while keeping the needle in place. Push the Plunger Rod all the way down as far as it will go to inject all of the medicine.<br/><br/><span class=\\\"Bold\\\">Note:</span> It is normal to feel some resistance.<br/><br/>You have to give the full dose to activate the Needle Shield.</td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"left\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">4</span></td><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Release the Plunger Rod</span></td><td align=\\\"left\\\" valign=\\\"top\\\"></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" valign=\\\"top\\\"><a name=\\\"f13\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"ebglyss-pfs-ifu-9-v1.jpg\\\"/></td><td align=\\\"justify\\\" valign=\\\"middle\\\">Lift your thumb to release the Plunger Rod until the Needle is covered by the Needle Shield.<br/><br/>Lightly press a cotton ball or gauze on the injection site if you see any blood.<br/><br/><span class=\\\"Bold\\\">Do not</span> rub your skin after the injection.</td></tr></tbody></table><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"53.300%\\\"/><col align=\\\"left\\\" width=\\\"46.700%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Disposing of EBGLYSS</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Dispose of (throw away) the used Prefilled Syringe</span><br/><a name=\\\"f14\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"ebglyss-pfs-ifu-10-v1.jpg\\\"/></td><td align=\\\"left\\\" valign=\\\"middle\\\">Put the used EBGLYSS Prefilled Syringe and Needle Cap in an FDA-cleared sharps disposal container right away after use.<br/></td></tr><tr><td align=\\\"left\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Do not</span> throw away (dispose of) the EBGLYSS Prefilled Syringe in your household trash.<br/><br/>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:<br/><ul class=\\\"Disc\\\"><li>made of a heavy-duty plastic,</li><li>able to be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</li><li>upright and stable during use,</li><li>leak-resistant, and</li><li>properly labeled to warn of hazardous waste inside the container.</li></ul><br/>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container.<br/><br/>There may be local laws about how you should throw away needles and syringes.<br/><br/>For more information about safe sharps disposal, and for specific information about sharps disposal in the state you live in, go to the FDA website at: http://www.fda.gov/safesharpsdisposal<br/><br/><span class=\\\"Bold\\\">Do not</span> recycle your used sharps disposal container.<br/></td></tr></tbody></table><p><span class=\\\"Bold\\\">Storing EBGLYSS</span></p><ul class=\\\"Disc\\\"><li>Store your Prefilled Syringe in a refrigerator between 36°F to 46°F (2°C to 8°C).</li><li>EBGLYSS can be stored at room temperature up to 7 days in the original carton. <span class=\\\"Bold\\\">Do not</span> store above 86°F (30°C). Throw away (dispose of) EBGLYSS that has been left at room temperature for longer than 7 days.</li><li>Store your Prefilled Syringe in the original carton to protect from light until use.</li><li><span class=\\\"Bold\\\">Do not</span> freeze your Prefilled Syringe. <span class=\\\"Bold\\\">Do not</span> shake your Prefilled Syringe.</li><li><span class=\\\"Bold\\\">Do not</span> microwave your Prefilled Syringe, or run hot water over it, or leave it in direct sunlight.</li><li>Throw away (dispose of) your Prefilled Syringe if any of the above conditions are not followed.</li></ul><p><span class=\\\"Bold\\\">Keep your Prefilled Syringes and all medicines out of the reach of children</span>.</p><table class=\\\"Noautorules\\\" width=\\\"100%\\\"><col align=\\\"left\\\" width=\\\"52.867%\\\"/><col align=\\\"left\\\" width=\\\"19.233%\\\"/><col align=\\\"left\\\" width=\\\"27.900%\\\"/><tbody class=\\\"Headless\\\"><tr><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">If you have more questions about how to use the EBGLYSS Prefilled Syringe:</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"bottom\\\"><ul class=\\\"Disc\\\"><li>Call your healthcare provider</li></ul></td><td align=\\\"center\\\" rowspan=\\\"3\\\" valign=\\\"middle\\\"><a name=\\\"f15\\\"></a><img alt=\\\"Figure\\n\\\" src=\\\"qr-v1.jpg\\\"/></td><td align=\\\"left\\\" rowspan=\\\"3\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">Scan this code to launch www.ebglyss.com</span></td></tr><tr><td align=\\\"left\\\" valign=\\\"bottom\\\"><ul class=\\\"Disc\\\"><li>Call 1-800-Lilly-Rx (1-800-545-5979)</li></ul></td></tr><tr><td align=\\\"left\\\" valign=\\\"bottom\\\"><ul class=\\\"Disc\\\"><li>Visit www.ebglyss.com</li></ul></td></tr></tbody></table><p><span class=\\\"Bold\\\">Read the Patient Information insert for EBGLYSS inside this box to learn more about your medicine.</span></p><p>Eli Lilly and Company</p><p>Indianapolis, IN 46285, USA</p><p>US License Number 1891</p><p>EBGLYSS is a trademark of Eli Lilly and Company.</p><p>Copyright © 2024, Eli Lilly and Company. All rights reserved.</p><p>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</p><p>Issued: September 2024</p><p>EBG-0001-PFS-IFU-202409</p></section>\",\n            \"mechanismOfAction\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43679-0\\\"><a name=\\\"s37\\\"></a><a name=\\\"section-10.1\\\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\\\"First\\\">Lebrikizumab-lbkz is an IgG4 monoclonal antibody that binds with high affinity and slow off-rate to interleukin (IL)-13 and allows IL-13 to bind to IL-13Rα1 but inhibits human IL-13 signaling through the IL-4Rα/IL-13Rα1 receptor complex. IL-13 is a naturally occurring cytokine that is involved in Type 2 inflammation, which is an important component in the pathogenesis of atopic dermatitis. Lebrikizumab-lbkz inhibits IL-13-induced responses including the release of proinflammatory cytokines, chemokines and IgE. Lebrikizumab-lbkz-bound IL-13 can still bind IL-13Rα2 allowing subsequent internalization and natural clearance of IL-13.</p></section>\",\n            \"contraindications\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34070-3\\\"><a name=\\\"s10\\\"></a><a name=\\\"section-4\\\"></a><p></p><h1>4 CONTRAINDICATIONS</h1><p class=\\\"First\\\">EBGLYSS is contraindicated in patients with prior serious hypersensitivity to lebrikizumab-lbkz or any excipients of EBGLYSS <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s12\\\">5.1</a>)]</span>.</p></section>\",\n            \"highlights\": {\n                \"dosageAndAdministration\": \"<div><ul class=\\\"Disc\\\"><li>Prior to EBGLYSS treatment, complete all age-appropriate vaccinations according to current immunization guidelines. (<a href=\\\"#s3\\\">2.1</a>)</li><li>The recommended dosage of EBGLYSS is 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg (one injection) every 2 weeks until Week 16 or later, when adequate clinical response is achieved. The maintenance dose is EBGLYSS 250 mg every 4 weeks. (<a href=\\\"#s4\\\">2.2</a>)</li><li>Administer by subcutaneous injection. (<a href=\\\"#s7\\\">2.4</a>)</li></ul></div>\"\n            }\n        }\n    },\n    {\n        \"drugName\": \"Taltz\",\n        \"setId\": \"ac96658a-d7dc-4c7c-8928-2adcdf4318b2\",\n        \"slug\": \"taltz-ac96658\",\n        \"labeler\": \"Lilly\",\n        \"label\": {\n            \"genericName\": \"ixekizumab\",\n            \"labelerName\": \"Eli Lilly and Company\",\n            \"productType\": \"HUMAN PRESCRIPTION DRUG LABEL\",\n            \"effectiveTime\": \"20241113\",\n            \"title\": \"TALTZ\",\n            \"indicationsAndUsage\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34067-9\\\"><a name=\\\"s1\\\"></a><a name=\\\"section-1\\\"></a><p></p><h1>1 INDICATIONS AND USAGE</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s2\\\"></a><a name=\\\"section-1.1\\\"></a><p></p><h2>1.1 Plaque Psoriasis</h2><p class=\\\"First\\\">         TALTZ<span class=\\\"Sup\\\">®</span> is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s3\\\"></a><a name=\\\"section-1.2\\\"></a><p></p><h2>1.2 Psoriatic Arthritis</h2><p class=\\\"First\\\">TALTZ is indicated for the treatment of adult patients with active psoriatic arthritis.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s4\\\"></a><a name=\\\"section-1.3\\\"></a><p></p><h2>        1.3 Ankylosing Spondylitis</h2><p class=\\\"First\\\">         TALTZ is indicated for the treatment of adult patients with active ankylosing spondylitis.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s4a\\\"></a><a name=\\\"section-1.4\\\"></a><p></p><h2>1.4 Non-radiographic Axial Spondyloarthritis</h2><p class=\\\"First\\\">         TALTZ is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.</p></div></section>\",\n            \"dosageAndAdministration\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34068-7\\\"><a name=\\\"s5\\\"></a><a name=\\\"section-2\\\"></a><p></p><h1>2 DOSAGE AND ADMINISTRATION</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s5a\\\"></a><a name=\\\"section-2.1\\\"></a><p></p><h2>2.1 Testing and Procedures Prior to Treatment Initiation</h2><p class=\\\"First\\\">Perform the following evaluations prior to TALTZ initiation:</p><ul class=\\\"Disc\\\"><li>Evaluate patients for tuberculosis (TB) infection. TALTZ initiation is not recommended in patients with active TB infection. Initiate treatment of latent TB prior to initiation of TALTZ <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s16\\\">5.2</a>)]</span>.</li><li>Complete all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with TALTZ <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s19\\\">5.6</a>)]</span>.</li></ul></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s6\\\"></a><a name=\\\"section-2.2\\\"></a><p></p><h2>2.2 Recommended Dosage in Adult Plaque Psoriasis</h2><p class=\\\"First\\\">TALTZ is administered by subcutaneous injection. The recommended dosage in adults with moderate-to-severe plaque psoriasis is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s7\\\"></a><a name=\\\"section-2.3\\\"></a><p></p><h2>2.3 Recommended Dosage in Pediatric Plaque Psoriasis</h2><p class=\\\"First\\\">         TALTZ is administered by subcutaneous injection every 4 weeks (Q4W). The recommended dosage in pediatric patients from 6 to less than 18 years of age with moderate-to-severe plaque psoriasis is based on the following weight categories.</p><a name=\\\"t1\\\"></a><table width=\\\"100%\\\"><caption><span>Table 1: Recommended Dosage for Pediatric Patients 6 Years of Age and Older with Plaque Psoriasis</span></caption><col align=\\\"left\\\" width=\\\"29.133%\\\"/><col align=\\\"left\\\" width=\\\"32.533%\\\"/><col align=\\\"left\\\" width=\\\"38.333%\\\"/><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Pediatric Patient's Weight</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Starting Dose (Week 0)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Dose every 4 weeks (Q4W) Thereafter</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Greater than 50 kg</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">160 mg (two 80 mg injections)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">80 mg</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">25 to 50 kg</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">80 mg</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">40 mg</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\">Less than 25 kg</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">40 mg</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">20 mg</td></tr></tbody></table></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s8\\\"></a><a name=\\\"section-2.4\\\"></a><p></p><h2>2.4 Recommended Dosage in Psoriatic Arthritis</h2><p class=\\\"First\\\">The recommended dosage is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.</p><p>For psoriatic arthritis patients with coexistent moderate-to-severe plaque psoriasis, use the dosing regimen for adult plaque psoriasis <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s6\\\">2.2</a>)]</span>.</p><p>TALTZ may be administered alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s9\\\"></a><a name=\\\"section-2.5\\\"></a><p></p><h2>2.5 Recommended Dosage in Ankylosing Spondylitis</h2><p class=\\\"First\\\">         The recommended dosage is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s10\\\"></a><a name=\\\"section-2.6\\\"></a><p></p><h2>2.6 Recommended Dosage in Non-radiographic Axial Spondyloarthritis</h2><p class=\\\"First\\\">The recommended dosage is 80 mg by subcutaneous injection every 4 weeks.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s11\\\"></a><a name=\\\"section-2.7\\\"></a><p></p><h2>2.7 Preparation and Administration Instructions</h2><p class=\\\"First\\\">         TALTZ is intended for use under the guidance and supervision of a healthcare provider. Adult patients may self-inject or caregivers may give injections of TALTZ after training in subcutaneous injection technique using the autoinjector or prefilled syringe. Safety and effectiveness of pediatric self-administration has not been established. Therefore, TALTZ should be administered to pediatric patients by a healthcare provider or by a caregiver who has received training and demonstrated proper subcutaneous injection technique.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>TALTZ 20 mg and 40 mg doses prepared from the TALTZ 80 mg/mL prefilled syringe should only be administered by a qualified healthcare professional <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s11a\\\">2.8</a>)]</span>.</p><p>         The TALTZ “Instructions for Use” contains more detailed instructions on the preparation and administration of TALTZ <span class=\\\"Italics\\\">[see Instructions for Use]</span>.</p><p>         Before injection, remove TALTZ autoinjector or TALTZ prefilled syringe from the refrigerator and allow TALTZ to reach room temperature (30 minutes) without removing the needle cap. Inspect TALTZ visually for particulate matter and discoloration prior to administration. TALTZ is a clear and colorless to slightly yellow solution. Do not use if the liquid contains visible particles, is discolored or cloudy (other than clear and colorless to slightly yellow).</p><p>         Administer each injection at a different anatomic location (such as upper arms, thighs or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, indurated or affected by psoriasis. Administration of TALTZ in the upper, outer arm may be performed by a caregiver or healthcare provider <span class=\\\"Italics\\\">[see Instructions for Use]</span>.</p><p>         TALTZ does not contain preservatives, therefore discard any unused product.</p><p>         If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s11a\\\"></a><a name=\\\"section-2.8\\\"></a><p></p><h2 style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span> 2.8 Alternative Preparation Instructions of TALTZ Doses for Pediatric Patients with Plaque Psoriasis Weighing 50 kg or Less</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>If the 20 mg/0.25 mL or 40 mg/0.5 mL prefilled syringe is unavailable, TALTZ doses of 20 mg or 40 mg for pediatric patients with plaque psoriasis <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s7\\\">2.3</a>)]</span> must be manually prepared according to the steps below using only the TALTZ 80 mg/mL prefilled syringe. The preparation and administration of the 20 mg and 40 mg doses should only be performed by a qualified healthcare professional. For additional preparation and administration instructions, <span class=\\\"Italics\\\">[see Dosage and Administration (<a href=\\\"#s11\\\">2.7</a>)]</span>.</p><ol class=\\\"Arabic\\\"><li>            Gather the following necessary supplies for preparation:<ul class=\\\"Disc\\\"><li>0.5 mL or 1 mL disposable syringe</li><li>Sterile needle for withdrawal</li><li>27-gauge sterile needle for administration</li><li>Sterile, clear glass vial.</li></ul></li><li>            Expel the entire contents of the prefilled syringe into the sterile vial. DO NOT shake or swirl the vial. Do not add other medications to solutions containing TALTZ.</li><li>            Using the 0.5 mL or 1 mL disposable syringe and sterile needle, withdraw the prescribed dose from the vial (0.25 mL for 20 mg; 0.5 mL for 40 mg).</li><li>            Remove the needle from the syringe and replace it with a 27-gauge needle prior to administering TALTZ.</li></ol><p><span class=\\\"Italics\\\">Storage of Prepared TALTZ</span></p><p>             If necessary, TALTZ 20 mg or 40 mg doses prepared from an 80 mg/mL prefilled syringe may be stored at room temperature for up to 4 hours from first puncturing the sterile vial.</p></div></section>\",\n            \"dosageFormsAndStrengths\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43678-2\\\"><a name=\\\"s12\\\"></a><a name=\\\"section-3\\\"></a><p></p><h1>3 DOSAGE FORMS AND STRENGTHS</h1><p class=\\\"First\\\">TALTZ is a clear and colorless to slightly yellow solution available as:</p><ul class=\\\"Disc\\\"><li>Injection: 80 mg/mL solution of TALTZ in a single-dose prefilled autoinjector </li><li>Injection: 80 mg/mL solution of TALTZ in a single-dose prefilled syringe</li><li>Injection: 40 mg/0.5 mL solution of TALTZ in a single-dose prefilled syringe</li><li>Injection: 20 mg/0.25 mL solution of TALTZ in a single-dose prefilled syringe</li></ul></section>\",\n            \"warningsAndPrecautions\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"43685-7\\\"><a name=\\\"s14\\\"></a><a name=\\\"section-5\\\"></a><p></p><h1>5 WARNINGS AND PRECAUTIONS</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s15\\\"></a><a name=\\\"section-5.1\\\"></a><p></p><h2>5.1 Infections</h2><p class=\\\"First\\\">         TALTZ may increase the risk of infection. In clinical trials in adult patients with plaque psoriasis, the TALTZ group had a higher rate of infections than the placebo group (27% vs. 23%). Upper respiratory tract infections, oral candidiasis, conjunctivitis and tinea infections occurred more frequently in the TALTZ group than in the placebo group. A similar increase in risk of infection was seen in placebo-controlled trials in patients with pediatric psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s21\\\">6.1</a>)]</span>.</p><p style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>In the postmarketing setting, serious bacterial, viral, and fungal opportunistic infections have been reported in patients receiving IL-17 inhibitors including TALTZ. Instruct patients treated with TALTZ to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a serious infection or is not responding to standard therapy, monitor the patient closely and discontinue TALTZ until the infection resolves.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s16\\\"></a><a name=\\\"section-5.2\\\"></a><p></p><h2>5.2 Pre-treatment Evaluation for Tuberculosis</h2><p class=\\\"First\\\">Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with TALTZ. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering TALTZ. Consider anti-TB therapy prior to initiating TALTZ in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving TALTZ should be monitored closely for signs and symptoms of active TB during and after treatment.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s17\\\"></a><a name=\\\"section-5.3\\\"></a><p></p><h2>5.3 Hypersensitivity</h2><p class=\\\"First\\\">Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the TALTZ group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post marketing use with TALTZ <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s21\\\">6.1</a>, <a href=\\\"#s39\\\">6.3</a>)]</span>. If a serious hypersensitivity reaction occurs, discontinue TALTZ immediately and initiate appropriate therapy.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"e18\\\"></a><a name=\\\"section-5.4\\\"></a><p></p><h2 style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>5.4 Eczematous Eruptions</h2><p class=\\\"First\\\" style=\\\"border-left:1px solid;\\\"><span class=\\\"XmChange\\\"></span>In the postmarketing setting, cases of severe eczematous eruptions, including atopic dermatitis-like eruptions, dyshidrotic eczema, and erythroderma were reported in patients receiving TALTZ; some cases resulted in hospitalization. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of TALTZ. Treatment may need to be discontinued to resolve the eczematous eruption. Some patients with limited psoriasis treatment options were successfully treated for eczema while continuing TALTZ.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s18\\\"></a><a name=\\\"section-5.5\\\"></a><p></p><h2>5.5 Inflammatory Bowel Disease</h2><p class=\\\"First\\\">Patients treated with TALTZ may be at increased risk of inflammatory bowel disease. In clinical trials, Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the TALTZ group than the placebo control group <span class=\\\"Italics\\\">[see Adverse Reactions (<a href=\\\"#s21\\\">6.1</a>)]</span>. During TALTZ treatment, monitor for onset or exacerbation of inflammatory bowel disease and if IBD occurs, discontinue TALTZ and initiate appropriate medical management.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s19\\\"></a><a name=\\\"section-5.6\\\"></a><p></p><h2>5.6 Immunizations</h2><p class=\\\"First\\\">Prior to initiating therapy with TALTZ, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TALTZ. No data are available on the response to live vaccines.</p></div></section>\",\n            \"adverseReactions\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34084-4\\\"><a name=\\\"s20\\\"></a><a name=\\\"section-6\\\"></a><p></p><h1>6 ADVERSE REACTIONS</h1><p class=\\\"First\\\">The following adverse drug reactions are discussed in greater detail in other sections of the label:</p><ul class=\\\"Disc\\\"><li>Infections <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s15\\\">5.1</a>)]</span></li><li>Hypersensitivity Reactions <span class=\\\"Italics\\\">[see Contraindications (<a href=\\\"#s13\\\">4</a>) and Warnings and Precautions (<a href=\\\"#s17\\\">5.3</a>)]</span></li><li>Eczematous Eruptions <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#e18\\\">5.4</a>)]</span></li><li>Inflammatory Bowel Disease <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s18\\\">5.5</a>)]</span></li></ul><div class=\\\"Section\\\" data-sectioncode=\\\"90374-0\\\"><a name=\\\"s21\\\"></a><a name=\\\"section-6.1\\\"></a><p></p><h2>6.1 Clinical Trials Experience</h2><p class=\\\"First\\\">Because clinical trials are conducted under widely varying and controlled conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s22\\\"></a><a name=\\\"section-6.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Adult Plaque Psoriasis</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s23\\\"></a><a name=\\\"section-6.1.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Weeks 0 to 12</span>:</p><p>Three placebo-controlled trials in subjects with plaque psoriasis were integrated to evaluate the safety of TALTZ compared to placebo for up to 12 weeks. A total of 1167 subjects (mean age 45 years; 66% men; 94% White) with plaque psoriasis received TALTZ (160 mg at Week 0, 80 mg every 2 weeks [Q2W] for 12 weeks) subcutaneously. In two of the trials, the safety of TALTZ (use up to 12 weeks) was also compared with an active comparator, U.S. approved etanercept <span class=\\\"Italics\\\">[see Clinical Studies (<a href=\\\"#s68\\\">14</a>)]</span>.</p><p>In the 12-week, placebo-controlled period, adverse events occurred in 58% of the TALTZ Q2W group (2.5 per subject-year of follow-up) compared with 47% of the placebo group (2.1 per subject-year of follow-up). Serious adverse events occurred in 2% of the TALTZ group (0.07 per subject-year of follow-up), and in 2% of the placebo group (0.07 per subject-year of follow-up).</p><p><a href=\\\"#t2\\\">Table 2</a> summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher rate in the TALTZ group than in the placebo group during the 12-week placebo-controlled period of the pooled clinical trials.</p><a name=\\\"t2\\\"></a><table width=\\\"100%\\\"><caption><span>Table 2: Adverse Reactions Occurring in ≥1% of the TALTZ Group and More Frequently than in the Placebo Group in the Plaque Psoriasis Clinical Trials through Week 12</span></caption><col align=\\\"left\\\" width=\\\"33.833%\\\"/><col align=\\\"left\\\" width=\\\"22.056%\\\"/><col align=\\\"left\\\" width=\\\"22.056%\\\"/><col align=\\\"left\\\" width=\\\"22.056%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Upper respiratory tract infections cluster includes nasopharyngitis and rhinovirus infection.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"4\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> U.S. approved etanercept.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Adverse Reactions</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ 80 mg Q2W</span><br/><span class=\\\"Bold\\\">(N=1167) n (%)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Etanercept</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">b</span></span><br/><span class=\\\"Bold\\\">(N=287) n (%)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span><br/><span class=\\\"Bold\\\">(N=791) n (%)</span></td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Injection site reactions</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">196 (17)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">32 (11)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">26 (3)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Upper respiratory tract infections</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">a</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">163 (14)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">23 (8)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">101 (13)</td></tr><tr><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Nausea</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">23 (2)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1 (&lt;1)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">5 (1)</td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Tinea infections</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">17 (2)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1 (&lt;1)</td></tr></tbody></table><p>Adverse reactions that occurred at rates less than 1% in the TALTZ group and more frequently than in the placebo group during the 12-week induction period included rhinitis, oral candidiasis, urticaria, influenza, conjunctivitis, inflammatory bowel disease, and angioedema.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s24\\\"></a><a name=\\\"section-6.1.1.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Weeks 13 to 60</span>:</p><p>A total of 332 subjects received the recommended maintenance regimen of TALTZ 80 mg dosed every 4 weeks.</p><p>During the maintenance period (Weeks 13 to 60), adverse events occurred in 80% of subjects treated with TALTZ (1.0 per subject-year of follow-up) compared to 58% of subjects treated with placebo (1.1 per subject-year of follow-up). Serious adverse events were reported in 4% of subjects treated with TALTZ (0.05 per subject-year of follow-up) and none in the subjects treated with placebo.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s25\\\"></a><a name=\\\"section-6.1.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Weeks 0 to 60</span>:</p><p>Over the entire treatment period (Weeks 0 to 60), adverse events were reported in 67% of subjects treated with TALTZ (1.4 per subject-year of follow-up) compared to 48% of subjects treated with placebo (2.0 per subject-year of follow-up). Serious adverse events were reported in 3% of subjects treated with TALTZ (0.06 per subject-year of follow-up), and in 2% of subjects treated with placebo (0.06 per subject-year of follow-up).</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s26\\\"></a><a name=\\\"section-6.1.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Specific Adverse Drug Reactions</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s27\\\"></a><a name=\\\"section-6.1.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Injection Site Reactions</span></p><p>The most frequent injection site reactions were erythema and pain. Most injection site reactions were mild-to-moderate in severity and did not lead to discontinuation of TALTZ.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s28\\\"></a><a name=\\\"section-6.1.3.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Infections</span></p><p>In the 12-week, placebo-controlled period of the clinical trials in plaque psoriasis, infections occurred in 27% of subjects treated with TALTZ (1.2 per subject-year of follow-up) compared to 23% of subjects treated with placebo (1.0 per subject-year of follow-up). Serious infections occurred in 0.4% of subjects treated with TALTZ (0.02 per subject-year of follow-up) and in 0.4% of subjects treated with placebo (0.02 per subject-year of follow-up) <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s15\\\">5.1</a>)]</span>.</p><p>During the maintenance treatment period (Weeks 13 to 60), infections occurred in 57% of subjects treated with TALTZ (0.70 per subject-year of follow-up) compared to 32% of subjects treated with placebo (0.61 per subject-year of follow-up). Serious infections occurred in 0.9% of subjects treated with TALTZ (0.01 per subject-year of follow-up) and none in the subjects treated with placebo.</p><p>Over the entire treatment period (Weeks 0 to 60), infections were reported in 38% of subjects treated with TALTZ (0.83 per subject-year of follow-up) compared to 23% of subjects treated with placebo (1.0 per subject-year of follow-up). Serious infections occurred in 0.7% of subjects treated with TALTZ (0.02 per subject-year of follow-up), and in 0.4% of subject treated with placebo (0.02 per subject-year of follow-up).</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s28a\\\"></a><a name=\\\"section-6.1.3.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Inflammatory Bowel Disease</span></p><p>In adult subjects with plaque psoriasis, Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the TALTZ 80 mg Q2W group (Crohn's disease 0.1%, ulcerative colitis 0.2%) than the placebo group (0%) during the 12-week, placebo-controlled period in clinical trials <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s18\\\">5.5</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s29\\\"></a><a name=\\\"section-6.1.3.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Laboratory Assessment of Cytopenia</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s30\\\"></a><a name=\\\"section-6.1.3.4.1\\\"></a><p></p><p class=\\\"First\\\">Neutropenia</p><p>Over the entire treatment period (Weeks 0 to 60), neutropenia occurred in 11% of subjects treated with TALTZ (0.24 per subject-year of follow-up) compared to 3% of subjects treated with placebo (0.14 per subject-year of follow-up). In subjects treated with TALTZ, the incidence rate of neutropenia during Weeks 13 to 60 was lower than the incidence rate during Weeks 0 to 12.</p><p>In the 12-week, placebo-controlled period, neutropenia ≥ Grade 3 (&lt;1,000 cells/mm<span class=\\\"Sup\\\">3</span>) occurred in 0.2% of the TALTZ group (0.007 per subject-year of follow-up) compared to 0.1% of the placebo group (0.006 per subject-year of follow-up). The majority of cases of neutropenia were either Grade 2 (2% for TALTZ 80 mg Q2W versus 0.3% for placebo; ≥1,000 to &lt;1,500 cells/mm<span class=\\\"Sup\\\">3</span>) or Grade 1 (7% for TALTZ 80 mg Q2W versus 3% for placebo; ≥1,500 cells/mm<span class=\\\"Sup\\\">3</span> to ˂2,000 cells/mm<span class=\\\"Sup\\\">3</span>). Neutropenia in the TALTZ group was not associated with an increased rate of infection compared to the placebo group.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s31\\\"></a><a name=\\\"section-6.1.3.4.2\\\"></a><p></p><p class=\\\"First\\\">Thrombocytopenia</p><p>Ninety eight percent of cases of thrombocytopenia were Grade 1 (3% for TALTZ 80 mg Q2W versus 1% for placebo; ≥75,000 cells/mm<span class=\\\"Sup\\\">3</span> to &lt;150,000 cells/mm<span class=\\\"Sup\\\">3</span>). Thrombocytopenia in subjects treated with TALTZ was not associated with an increased rate of bleeding compared to subjects treated with placebo.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s32\\\"></a><a name=\\\"section-6.1.3.5\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Active Comparator Trials</span></p><p>In the two clinical trials that included an active comparator, the rate of serious adverse events during weeks zero to twelve was 0.7% for U.S. approved etanercept and 2% for TALTZ 80 mg Q2W, and the rate of discontinuation from adverse events was 0.7% for U.S. approved etanercept and 2% for TALTZ 80 mg Q2W. The incidence of infections was 18% for U.S. approved etanercept and 26% for TALTZ 80 mg Q2W. The rate of serious infections was 0.3% for both TALTZ 80 mg Q2W and U.S. approved etanercept.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s32a\\\"></a><a name=\\\"section-6.1.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Pediatric Plaque Psoriasis</span></p><p>TALTZ was evaluated in a placebo-controlled trial in pediatric subjects with moderate-to-severe psoriasis 6 to less than 18 years of age. A total of 171 subjects were studied (115 subjects on TALTZ and 56 subjects on placebo). Overall, the safety profile observed in pediatric subjects with plaque psoriasis treated with TALTZ every 4 weeks is consistent with the safety profile in adult subjects with plaque psoriasis with the exception of the frequencies of conjunctivitis (2.6%), influenza (1.7%), and urticaria (1.7%).</p><p>In this clinical trial, Crohn's disease occurred at a greater frequency in the TALTZ group (0.9%) than the placebo group (0%) during the 12-week, placebo-controlled period. Crohn's disease occurred in a total of 4 TALTZ treated subjects (2.0%) in the clinical trial <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s18\\\">5.5</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s33\\\"></a><a name=\\\"section-6.1.5\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Psoriatic Arthritis</span></p><p>TALTZ was studied in two placebo-controlled trials in patients with psoriatic arthritis. A total of 678 patients were studied (454 patients on TALTZ and 224 on placebo). A total of 229 patients in these trials received TALTZ 160 mg at Week 0, followed by 80 mg every 4 weeks (Q4W). Overall, the safety profile observed in patients with psoriatic arthritis treated with TALTZ Q4W is consistent with the safety profile in adult patients with plaque psoriasis with the exception of the frequencies of influenza (1.3%) and conjunctivitis (1.3%).</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s34\\\"></a><a name=\\\"section-6.1.6\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Ankylosing Spondylitis</span></p><p>TALTZ was studied in two placebo-controlled trials in patients with ankylosing spondylitis. A total of 566 patients were studied (376 patients on TALTZ and 190 on placebo). A total of 195 patients in these trials received TALTZ 80 or 160 mg at Week 0, followed by 80 mg every 4 weeks (Q4W). Overall, the safety profile observed in patients with ankylosing spondylitis treated with TALTZ Q4W is consistent with the safety profile in adult patients with plaque psoriasis.</p><p>In adult patients with ankylosing spondylitis, Crohn's disease and ulcerative colitis, including exacerbations, occurred in 2 patients (1.0%) and 1 patient (0.5%), respectively, in the TALTZ 80 mg Q4W group and 1 patient (0.5%) and 0%, respectively, in the placebo group during the 16-week, placebo-controlled period in clinical trials. Of these patients, serious events occurred in 1 patient in the TALTZ 80 mg Q4W group and 1 patient in the placebo group <span class=\\\"Italics\\\">[see Warnings and Precautions (<a href=\\\"#s18\\\">5.5</a>)]</span>.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s34a\\\"></a><a name=\\\"section-6.1.7\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Non-radiographic Axial Spondyloarthritis</span></p><p>TALTZ was studied in a placebo-controlled trial in patients with non-radiographic axial spondyloarthritis. A total of 303 patients were studied (198 patients on TALTZ and 105 on placebo). A total of 96 patients in this trial received TALTZ 80 or 160 mg at Week 0, followed by 80 mg every 4 weeks (Q4W). Overall, the safety profile observed in patients with non-radiographic axial spondyloarthritis treated with TALTZ 80 mg Q4W up to Week 16 is consistent with the previous experience of TALTZ in other indications.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"88830-5\\\"><a name=\\\"s35\\\"></a><a name=\\\"section-6.2\\\"></a><p></p><h2>6.2 Immunogenicity</h2><p class=\\\"First\\\">As with all therapeutic proteins there is the potential for immunogenicity with TALTZ. The assay to test for neutralizing antibodies has limitations detecting neutralizing antibodies in the presence of ixekizumab; therefore, the incidence of neutralizing antibodies development could be underestimated.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s36\\\"></a><a name=\\\"section-6.2.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Plaque Psoriasis Population</span></p><p>By Week 12, approximately 9% of adult subjects treated with TALTZ every 2 weeks developed antibodies to ixekizumab. Approximately 22% of subjects treated with TALTZ at the recommended dosing regimen developed antibodies to ixekizumab during the 60-week treatment period. The clinical effects of antibodies to ixekizumab are dependent on the antibody titer; higher antibody titers were associated with decreasing drug concentration and clinical response.</p><p>Of the adult subjects who developed antibodies to ixekizumab during the 60-week treatment period, approximately 10%, which equates to 2% of subjects treated with TALTZ at the recommended dosing regimen, had antibodies that were classified as neutralizing. Neutralizing antibodies were associated with reduced drug concentrations and loss of efficacy.</p><p>In pediatric psoriasis subjects treated with ixekizumab at the recommended dosing regimen up to 12 weeks, 21 subjects (18%) developed anti-drug antibodies, 5 subjects (4%) had confirmed neutralizing antibodies associated with low drug concentrations. No conclusive evidence could be obtained on the potential association of neutralizing antibodies and clinical response and/or adverse events due to small number of pediatric subjects in the study.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s37\\\"></a><a name=\\\"section-6.2.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Psoriatic Arthritis Population</span></p><p>For subjects treated with TALTZ 80 mg every 4 weeks for up to 52 weeks (PsA1), 11% developed anti-drug antibodies, and 8% had confirmed neutralizing antibodies.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s38\\\"></a><a name=\\\"section-6.2.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Ankylosing Spondylitis Population</span></p><p>For patients treated with TALTZ 80 mg every 4 weeks for up to 16 weeks (AS1, AS2), 5.2% developed anti-drug antibodies, and 1.5% had neutralizing antibodies.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s38a\\\"></a><a name=\\\"section-6.2.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Non-radiographic Axial Spondyloarthritis Population</span></p><p>Of patients treated with TALTZ 80 mg every 4 weeks for up to 52 weeks (nr-axSpA1), 8.9% developed anti-drug antibodies, all of which were low titer. No patient had neutralizing antibodies.</p><p>The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to TALTZ across indications or with the incidences of antibodies to other products may be misleading.</p></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"90375-7\\\"><a name=\\\"s39\\\"></a><a name=\\\"section-6.3\\\"></a><p></p><h2>6.3 Postmarketing Experience</h2><p class=\\\"First\\\">The following adverse reactions have been identified during post-approval use of TALTZ. Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to TALTZ exposure.</p><p><span class=\\\"Italics\\\">Immune system disorders:</span> anaphylaxis <span class=\\\"Italics\\\">[see Contraindications (<a href=\\\"#s13\\\">4</a>)]</span>.</p><p><span class=\\\"Italics\\\">Infections:</span> bacterial, viral, and fungal opportunistic infections, including cryptococcal meningoencephalitis, esophageal and disseminated mucocutaneous candidiasis, pulmonary tuberculosis, toxoplasmosis, varicella zoster virus reactivation, cytomegalovirus colitis, pulmonary aspergillosis.</p><p><span class=\\\"Italics\\\">Skin and subcutaneous tissue disorders:</span> Eczematous eruptions (erythroderma, atopic dermatitis-like eruptions, and dyshidrotic eczema).</p></div></section>\",\n            \"clinicalPharmacology\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34090-1\\\"><a name=\\\"s54\\\"></a><a name=\\\"section-9\\\"></a><p></p><h1>12 CLINICAL PHARMACOLOGY</h1><div class=\\\"Section\\\" data-sectioncode=\\\"43679-0\\\"><a name=\\\"s55\\\"></a><a name=\\\"section-9.1\\\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\\\"First\\\">Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of proinflammatory cytokines and chemokines.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"43681-6\\\"><a name=\\\"s56\\\"></a><a name=\\\"section-9.2\\\"></a><p></p><h2>12.2 Pharmacodynamics</h2><p class=\\\"First\\\">No formal pharmacodynamic studies have been conducted with TALTZ.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"43682-4\\\"><a name=\\\"s57\\\"></a><a name=\\\"section-9.3\\\"></a><p></p><h2>12.3 Pharmacokinetics</h2><p class=\\\"First\\\">The pharmacokinetic (PK) properties of ixekizumab were similar across the adult plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis indications.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s58\\\"></a><a name=\\\"section-9.3.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Absorption</span></p><p>Following a single subcutaneous dose of 160 mg in subjects with plaque psoriasis, ixekizumab reached peak mean (±SD) serum concentrations (C<span class=\\\"Sub\\\">max</span>) of 16.2 ±6.6 mcg/mL by approximately 4 days post dose.</p><p>Steady-state concentrations were achieved by Week 8 following the 160 mg starting dose and 80 mg every 2 weeks dosing regimen; the mean ±SD steady-state trough concentration was 9.3 ±5.3 mcg/mL. Steady-state concentrations were achieved approximately 10 weeks after switching from the 80 mg every 2 weeks dosing regimen to the 80 mg every 4 weeks dosing regimen at Week 12. The mean ±SD steady-state trough concentration was 3.5 ±2.5 mcg/mL.</p><p>In studies of subjects with plaque psoriasis, ixekizumab bioavailability ranged from 60% to 81% following subcutaneous injection. Administration of ixekizumab via injection in the thigh achieved a higher bioavailability relative to that achieved using other injection sites including the arm and abdomen.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s59\\\"></a><a name=\\\"section-9.3.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Distribution</span></p><p>The mean (geometric CV%) volume of distribution at steady-state was 7.11 L (29%) in subjects with plaque psoriasis.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s60\\\"></a><a name=\\\"section-9.3.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Elimination</span></p><p>The metabolic pathway of ixekizumab has not been characterized. As a humanized IgG4 monoclonal antibody ixekizumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.</p><p>The mean systemic clearance was 0.39 L/day (37%) and the mean (geometric CV%) half-life was 13 days (40%) in subjects with plaque psoriasis.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s61\\\"></a><a name=\\\"section-9.3.4\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Weight</span></p><p>Ixekizumab clearance and volume of distribution increase as body weight increases.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s62\\\"></a><a name=\\\"section-9.3.5\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Dose Linearity</span></p><p>Ixekizumab exhibited dose-proportional pharmacokinetics in subjects with plaque psoriasis over a dose range from 5 mg (not the recommended dose) to 160 mg following subcutaneous administration.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s63\\\"></a><a name=\\\"section-9.3.6\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Specific Populations</span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s63a\\\"></a><a name=\\\"section-9.3.6.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Age: </span></p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s63b\\\"></a><a name=\\\"section-9.3.6.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Geriatric Population</span></p><p>Population pharmacokinetic analysis indicated that age did not significantly influence the clearance of ixekizumab in adult subjects with plaque psoriasis. Subjects who are 65 years or older had a similar ixekizumab clearance as compared to subjects less than 65 years old.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s63c\\\"></a><a name=\\\"section-9.3.6.1.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Italics\\\">Pediatric Population</span></p><p>Pediatric psoriasis subjects (6 to less than 18 years of age) were administered ixekizumab at the recommended pediatric dosing regimen for 12 weeks. Subjects weighing &gt;50 kg and 25 to 50 kg had a mean ±SD steady-state trough concentration of 3.8 ±2.2 mcg/mL and 3.9 ±2.4 mcg/mL at Week 12, respectively. There were limited PK data (n=2) in subjects weighing &lt;25 kg at Week 12.</p></div></div></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s65\\\"></a><a name=\\\"section-9.3.7\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Drug Interaction Studies</span></p><p>Population PK data analyses indicated that the clearance of ixekizumab was not impacted by concomitant administration of methotrexate, or by prior exposure to methotrexate or adalimumab in patients with psoriatic arthritis.</p><p>Population PK data analyses indicated that the clearance of ixekizumab was not impacted by concomitant administration of oral corticosteroids, NSAIDs, or cDMARDs (sulfasalazine and methotrexate) in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.</p><p><span class=\\\"Italics\\\">Cytochrome P450 Substrates</span></p><p>No clinically significant changes in exposure of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate) or midazolam (CYP3A substrate) were observed in subjects with plaque psoriasis when used concomitantly with a single 160 mg dose of ixekizumab, or multiple doses of 80 mg every 2 weeks. The potential effect of ixekizumab on the CYP2D6 activity cannot be ruled out due to high variability in exposure (approximately ±2-fold) of dextromethorphan and its CYP2D6 metabolite dextrorphan in psoriasis subjects.</p></div></div></section>\",\n            \"clinicalStudies\": \"<section class=\\\"Section\\\" data-sectioncode=\\\"34092-7\\\"><a name=\\\"s68\\\"></a><a name=\\\"section-11\\\"></a><p></p><h1>14 CLINICAL STUDIES</h1><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s69\\\"></a><a name=\\\"section-11.1\\\"></a><p></p><h2>14.1 Adult Plaque Psoriasis</h2><p class=\\\"First\\\">Three multicenter, randomized, double-blind, placebo-controlled trials, Trials 1, 2, and 3 (NCT 01474512, NCT 01597245, NCT 01646177), enrolled a total of 3866 subjects 18 years of age and older with plaque psoriasis who had a minimum body surface area involvement of 10%, a static Physician Global Assessment (sPGA) score of ≥3 in the overall assessment (plaque thickness/induration, erythema, and scaling) of psoriasis on a severity scale of 0 to 5, a Psoriasis Area and Severity Index (PASI) score ≥12, and who were candidates for phototherapy or systemic therapy.</p><p>In all three trials, subjects were randomized to either placebo or TALTZ (80 mg every 2 weeks [Q2W]) for 12 weeks, following a 160 mg starting dose. In the two active comparator trials (Trials 2 and 3), subjects were also randomized to receive U.S. approved etanercept 50 mg twice weekly for 12 weeks.</p><p>All three trials assessed the changes from baseline to Week 12 in the two co-primary endpoints: 1) PASI 75, the proportion of subjects who achieved at least a 75% reduction in the PASI composite score that takes into consideration both the percentage of body surface area affected and the nature and severity of psoriatic changes (induration, erythema and scaling) within the affected regions, and 2) sPGA of “0” (clear) or “1” (minimal), the proportion of subjects with an sPGA 0 or 1 and at least a 2-point improvement.</p><p>Other evaluated outcomes included the proportion of subjects with an sPGA score of 0 (clear), a reduction of at least 90% in PASI (PASI 90), a reduction of 100% in PASI (PASI 100), and an improvement of itch severity as measured by a reduction of at least 4 points on an 11-point itch Numeric Rating Scale.</p><p>Subjects in all treatment groups had a median baseline PASI score ranging from approximately 17 to 18. Baseline sPGA score was severe or very severe in 51% of subjects in Trial 1, 50% in Trial 2, and 48% in Trial 3.</p><p>Of all subjects, 44% had received prior phototherapy, 49% had received prior conventional systemic therapy, and 26% had received prior biologic therapy for the treatment of psoriasis. Of the subjects who had received prior biologic therapy, 15% had received at least one anti-TNF alpha agent, and 9% had received an anti-IL 12/IL23. A total of 23% of study subjects had a history of psoriatic arthritis.</p><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s69a\\\"></a><a name=\\\"section-11.1.1\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Clinical Response at Week 12</span></p><p>The results of Trials 1, 2, and 3 are presented in <a href=\\\"#t3\\\">Table 3</a>.</p><a name=\\\"t3\\\"></a><table width=\\\"100%\\\"><caption><span>Table 3: Efficacy Results at Week 12 in Adults with Plaque Psoriasis in Trials 1, 2, and 3; NRI<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"17.286%\\\"/><col align=\\\"left\\\" width=\\\"15.000%\\\"/><col align=\\\"left\\\" width=\\\"12.500%\\\"/><col align=\\\"left\\\" width=\\\"15.000%\\\"/><col align=\\\"left\\\" width=\\\"12.500%\\\"/><col align=\\\"left\\\" width=\\\"15.000%\\\"/><col align=\\\"left\\\" width=\\\"12.714%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Abbreviations: N = number of patients in the intent-to-treat population; NRI = Non-Responder Imputation.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">b</span> At Week 0, subjects received 160 mg of TALTZ.</p></td></tr><tr><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">c</span> Co-primary endpoints.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"7\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">d</span> Itch NRS (≥4 improvement) in subjects with baseline Itch NRS ≥4. The number of ITT subjects with baseline Itch NRS Score ≥4 are as follows: Trial 1, TALTZ n=391, PBO n=374; Trial 2, TALTZ n=303, PBO n=135; Trial 3, TALTZ n=320, PBO n=158.</p></td></tr></tfoot><tbody class=\\\"Headless\\\"><tr class=\\\"First\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule Toprule\\\" rowspan=\\\"2\\\" valign=\\\"top\\\"></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Trial 1</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Trial 2</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule Toprule\\\" colspan=\\\"2\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Trial 3</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ 80 mg</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">b</span></span><br/><span class=\\\"Bold\\\">Q2W (N=433)</span><br/><span class=\\\"Bold\\\">n (%)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span><br/><span class=\\\"Bold\\\">(N=431)</span><br/><span class=\\\"Bold\\\">n (%)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ 80 mg</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">b</span></span><br/><span class=\\\"Bold\\\">Q2W (N=351)</span><br/><span class=\\\"Bold\\\">n (%)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span><br/><span class=\\\"Bold\\\">(N=168)</span><br/><span class=\\\"Bold\\\">n (%)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">TALTZ 80 mg</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">b</span></span><br/><span class=\\\"Bold\\\">Q2W (N=385)</span><br/><span class=\\\"Bold\\\">n (%)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Placebo</span><br/><span class=\\\"Bold\\\">(N=193)</span><br/><span class=\\\"Bold\\\">n (%)</span></td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">sPGA of “0” (clear) or “1” (minimal)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">354 (82)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">14 (3)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">292 (83)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">4 (2)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">310 (81)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">13 (7)</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"middle\\\"><span class=\\\"Bold\\\">sPGA of “0” (clear)</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">160 (37)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">147 (42)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1 (1)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">155 (40)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">PASI 75</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">c</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">386 (89)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">17 (4)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">315 (90)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">4 (2)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">336 (87)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">14 (7)</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">PASI 90</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">307 (71)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">2 (1)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">248 (71)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">1 (1)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">262 (68)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">6 (3)</td></tr><tr><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">PASI 100</span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">153 (35)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"middle\\\">142 (40)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">1 (1)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">145 (38)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">0</td></tr><tr class=\\\"Last\\\"><td align=\\\"center\\\" class=\\\"Botrule Lrule Rrule\\\" valign=\\\"top\\\"><span class=\\\"Bold\\\">Itch NRS (≥4 point improvement)</span><span class=\\\"Bold\\\"><span class=\\\"Sup\\\">d</span></span></td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">336 (86)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">58 (16)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">258 (85)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">19 (14)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">264 (83)</td><td align=\\\"center\\\" class=\\\"Botrule Rrule\\\" valign=\\\"top\\\">33 (21)</td></tr></tbody></table><p>Examination of age, gender, race, body weight, and previous treatment with a biologic did not identify differences in response to TALTZ among these subgroups at Week 12.</p><p>An integrated analysis of the U.S. sites in the two active comparator studies using U.S. approved etanercept, TALTZ demonstrated superiority to U.S. approved etanercept (50 mg twice weekly) on sPGA and PASI scores during the 12-week treatment period. The respective response rates for TALTZ 80 mg Q2W and U.S. approved etanercept 50 mg twice weekly were: sPGA of 0 or 1 (73% and 27%); PASI 75 (87% and 41%); sPGA of 0 (34% and 5%); PASI 90 (64% and 18%), and PASI 100 (34% and 4%).</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s69b\\\"></a><a name=\\\"section-11.1.2\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Maintenance and Durability of Response</span></p><p>To evaluate the maintenance and durability of response, subjects originally randomized to TALTZ and who were responders at Week 12 (i.e., sPGA of 0 or 1) in Trial 1 and Trial 2 were re-randomized to an additional 48 weeks of either a maintenance dose of TALTZ 80 mg Q4W (every 4 weeks) or placebo. Non-responders (sPGA &gt;1) at Week 12 and subjects who relapsed (sPGA ≥3) during the maintenance period were placed on TALTZ 80 mg Q4W.</p><p>For responders at Week 12, the percentage of subjects who maintained this response (sPGA 0 or 1) at Week 60 (48 weeks following re-randomization) in the integrated trials (Trial 1 and Trial 2) was higher for subjects treated with TALTZ 80 mg Q4W (75%) compared to those treated with placebo (7%).</p><p>For responders at Week 12 who were re-randomized to treatment withdrawal (i.e., placebo), the median time to relapse (sPGA ≥3) was 164 days in the integrated trials. Among these subjects, 66% regained a response of at least 0 or 1 on the sPGA within 12 weeks of restarting treatment with TALTZ 80 mg Q4W.</p></div><div class=\\\"Section\\\" data-sectioncode=\\\"42229-5\\\"><a name=\\\"s69c\\\"></a><a name=\\\"section-11.1.3\\\"></a><p></p><p class=\\\"First\\\"><span class=\\\"Underline\\\">Psoriasis Involving the Genital Area</span></p><p>A randomized, double-blind, placebo-controlled trial (Trial 4) was conducted in 149 adult subjects with plaque psoriasis who had a minimum body surface area (BSA) involvement of 1%, a sPGA score of ≥3 (moderate psoriasis), a sPGA of Genitalia score of ≥3 (moderate psoriasis involving the genital area), who failed to respond to or were intolerant of at least one topical therapy used for treatment of psoriasis affecting the genital area, and who were candidates for phototherapy and/or systemic therapy.</p><p>Subjects had a median baseline PASI score of approximately 12. Baseline BSA involvement was at least 10% for approximately 60% of the enrolled subjects. Baseline sPGA of Genitalia score was severe or very severe in approximately 42% of the subjects; baseline sPGA score was severe or very severe in approximately 47% of the subjects.</p><p>Subjects randomized to TALTZ received an initial dose of 160 mg followed by 80 mg every 2 weeks for 12 weeks. The trial evaluated the primary endpoint of the proportion of subjects who achieved a “0” (clear) or “1” (minimal) response at Week 12 on sPGA of Genitalia. Other evaluated outcomes at Week 12 included the proportion of subjects who achieved a sPGA score of “0” (clear) or “1” (minimal), improvement of genital itch severity as measured by a reduction of at least 4 points in the 11-point Genital Psoriasis Symptoms Scale (GPSS) score Itch numeric rating scale (NRS), and the patient-perceived impact of psoriasis affecting the genital area on limiting frequency of sexual activity (intercourse or other activities) as measured by the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 (In the past week how often did your genital psoriasis limit the frequency of your sexual activity?). SFQ Item 2 score ranges from 0 to 4 (0=never, 1=rarely, 2=sometimes, 3=often, 4=always); where higher scores indicate greater limitations on the frequency of sexual activity in the past week.</p><p>The results of Trial 4 are presented in <a href=\\\"#t4\\\">Table 4</a>.</p><a name=\\\"t4\\\"></a><table width=\\\"100%\\\"><caption><span>Table 4: Efficacy Results at Week 12 in Adults with Genital Psoriasis in Trial 4; NRI<span class=\\\"Sup\\\">a</span></span></caption><col align=\\\"left\\\" width=\\\"58.667%\\\"/><col align=\\\"left\\\" width=\\\"20.667%\\\"/><col align=\\\"left\\\" width=\\\"20.667%\\\"/><tfoot><tr class=\\\"First\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" valign=\\\"top\\\"><p class=\\\"First Footnote\\\"><span class=\\\"Sup\\\">a</span> Abbreviations: NRI = Non-Responder Imputation; GPSS = Genital Psoriasis Symptoms Scale; GenPs-SFQ = Genital Psoriasis Sexual Frequency Questionnaire.</p></td></tr><tr class=\\\"Last\\\"><td align=\\\"left\\\" colspan=\\\"3\\\" v"